Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05376839 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05376839 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 6 participants.
The verdict
NCT05376839, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the pharmacokinetics and safety of cedirogant following oral administration of multiple doses in adult participants with hepatic impairment and normal hepatic function.
Interventions
- DRUG Cedirogant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-07-06 |
| Est. Completion | 2022-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05376839
The ClinicalTrials.gov registry entry for NCT05376839 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cedirogant is the first listed.
NCT05376839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05376839 about?
NCT05376839 is a clinical study titled "A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment". The objective of this study is to evaluate the pharmacokinetics and safety of cedirogant following oral administration of multiple doses in adult participants with hepatic impairment and normal hepatic function.
What is the current status of trial NCT05376839?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-07-06. Estimated completion is 2022-11-08.
What interventions are being tested in trial NCT05376839?
The interventions under investigation include: Cedirogant (DRUG).
Who is sponsoring clinical trial NCT05376839?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.